Tekmira Stops Phase I Trial of Cholesterol Drug, Plans to Move New Agent into Clinical Trials Later This Year

While the drug was well tolerated and showed some signs of clinical activity, Tekmira said that it has put the phase I program on hold in order to select a new siRNA and drug-delivery formulation for development. The new agent is expected to be "several-fold more potent than the current formulation," the company said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.